Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding - Press release by Nastech Pharmaceutical Company Inc.


Home		Set as Homepage		Add to Favorite		Contact		Submit

09 January, 2009

search for

Categories

Politics & Government

Category: Press » Health & Fitness
Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding	Popularity: Views: 57

2007-12-05 06:02:08
	Nastech Pharmaceutical Company Inc.

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that they have entered into a feasibility study with an undisclosed global leader in the production of plasma products, to develop an alternative dosage form of Factor IX protein which is currently administered by injection to control and prevent bleeding in patients with hemophilia B. "We look forward to working with our new global partner to evaluate the feasibility of delivering Factor IX without an injection," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech. "Patients with hemophilia B, a result of deficiency in the Factor IX protein, require a lifetime of frequent injections in order to manage their condition. An alternative to these injections would be welcomed by patients and their caregivers." Factor IX is a protein produced naturally in the body that helps the blood to form clots. Hemophilia B, also known as Christmas disease, is a condition in which the body does not make enough Factor IX and is treated by injections of the protein. If a person does not have enough Factor IX and becomes injured, the blood will not form clots and they may bleed into and damage muscles and joints. About Nastech Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and our collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at . Nastech Forward Looking Statements Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events. Contacts: Nastech Ed Bell Director, Investor Relations (425) 908-3639
Specialized in:	Nastech Pharmaceutical Company - Nstk - Intranasal Drug Delivery - Intranasal - Systemic Transnasal Absorption Technology - Sta-t - Paracellular Transport System - Pts - Sexual Dysfunction - Erectile Dysfunction - Female Sexual Dysfunction - Fsd - Breakthrough Pain
URL:

Print press release

Send to a friend

Bookmark this page

Related Press releases

Corgentech Pain Drug, 4975, Demonstrates Statistically Significant Pain Reduction After Knee Replacement Surgeries (Popularity:

): Corgentech Inc. (Nasdaq: CGTK) today reported positive, top-line clinical data from a Phase 2 clinical trial in total knee replacement surgeries showing that 4975, the company's novel, long-acting, non-opioid drug candidate being developed for site-specific, moderate-to-severe pain, demonstrated pain reduction at all pre-specified time intervals in the study, including statistically significant pain relief at day one (p=0.0273) and at day 14 (p=0.0071). The difference in average daily pain scores between ...
Johnson & Johnson to Acquire Pfizer Consumer Healthcare; Combination Creates World's Premier Consumer Health Care Company (Popularity:

): Johnson & Johnson (NYSE: JNJ), the world's most comprehensive and broadly based manufacturer of health care products, today announced that it has entered into a definitive agreement to acquire Pfizer Consumer Healthcare for $16.6 billion in cash. The Johnson & Johnson Board of Directors has given approval to the transaction. Closing is subject to customary clearances, including the Hart-Scott-Rodino Antitrust Improvements Act and European Union merger control regulation. The transaction ...
TheTennisChannel.Com Celebrates Tennis' Premier Grass-Court Event with Content Package to Coincide with Wimbledon (Popularity:

): The Tennis Channel, the only 24-hour, television-based multimedia destination dedicated to tennis and the healthy, active lifestyle that surrounds it, has unveiled an online content package to coincide with Wimbledon, one of the most prestigious events in all of organized sports. In conjunction with London’s annual grass-court tennis tournament, www.TheTennisChannel.com features news, previews, updates, travel information, broadband video, message board access and a variety of other content fully dedicated to ...
Fat Fighter FBCx Receives Kosher Certification (Popularity:

): ArtJen Complexus Holdings Corp. is pleased to announce that they have received kosher certification from Rabbi Gabriel Zinner of Brooklyn, NY for FBCx, the fat fighting fiber tablet. The popularity of FBCx is steadily growing so we are very pleased to be able to provide FBCx as Kosher certified According to ArtJen President, Dr. Catherine Jen, kosher certification is further evidence of the high standards to which FBCx is manufactured ...
Top Malaysian Cancer Center Begins Treatments Using World's Most Versatile and Advanced Radiotherapy Machine (Popularity:

): A leading cancer center in Malaysia has begun offering patients state-of-the-art radiotherapy treatments using a new Trilogy(R) linear accelerator from Varian Medical Systems. The NCI Cancer Hospital in Nilai, south of Kuala Lumpur, has launched treatment programs offering the latest in high-precision radiotherapy techniques, including intensity modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT) and stereotactic radiosurgery. More than 40 patients have been treated on the versatile, all-in-one Trilogy machine since treatments ...

Press release home snapshot

Related Business

Depo-Provera: An Injectable Contraceptive (Popularity:

): American Academy of Family Physicians shares this handout with basic information on how this injectable contraceptive works. Study its effectiveness.
Medline Plus: Factor XII Deficiency (Popularity:

): Also known as Hageman factor, this is a congenital coagulation disorder that causes prolonged coagulation in a test tube but does not cause abnormal bleeding. Includes brief information.
An Institute for the Languages of Scotland: Feasibility Study (Popularity:

): The Carnegie Trust for the Universities of Scotland has funded this feasibility study to investigate the proposed establishment of ILS.
Beluk Power Factor Control from Illimite & the BLR series of PF control relays (Popularity:

): Beluk.com is the home of information on Beluk Power Factor Controllers. Details on individual models and power factor correction theory are included.
The Factor VIIa Source (Popularity:

): Information about topics related to the pathophysiology, pharmacology, and clinical aspects of bleeding, coagulation, and hemostasis, including information about recombinant coagulation Factor VIIa.
Birth Control Pills and Abnormal Bleeding (Popularity:

): Frequently asked questions and articles about oral contraceptives, including side effects, timing of use, effect on menstrual bleeding, and interactions with other medications.
Baby Center - Severe Bleeding (Popularity:

): Questions and informative answers on what to do and how to control severe bleeding on your child.
ActiveSizer (Popularity:

): Four controls in one: a form resizer; a splitter control that provides multiple split views on form; a scroller that allows the form contents to scroll when the form is too small and a subform hosting control that allows a form to display a child form in a panel. By Data Dynamics. [Component, Commercial]
First Aid - Bleeding (Popularity:

): Introduction into the different forms of bleeding; internal, external and uncontrolled bleeding. From the Malaysia First Online School Red Crescent Society.
Medline Plus: Factor VII Deficiency (Popularity:

): Brief information about this inherited bleeding disorder including causes, symptoms, and prognosis.